TY - JOUR A1 - Diepeveen, L. E. A1 - Laarakkers, C. M. M. A1 - Martos, G. A1 - Pawlak, M. E. A1 - Uguz, F. F. A1 - Verbene, K. E. S. A. A1 - van Swelm, R. P. L. A1 - Klaver, S. A1 - de Haan, A. F. J. A1 - Pitts, K. R. A1 - Bansal, S. S. A1 - Abbas, Ioana M. A1 - Fillet, M. A1 - Lefebvre, T. A1 - Geurts-Moespot, A. J. A1 - Girelli, D. A1 - Castagna, A. A1 - Herkert, M. A1 - Itkonen, O. A1 - Olbina, G. A1 - Tomosugi, N. A1 - Westerman, M. E. A1 - Delatour, V. A1 - Weykamp, C. W. A1 - Swinkels, D. W. T1 - Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material JF - Clinical Chemistry and Laboratory Medicine (CCLM) N2 - Hepcidin-25 concentrations measured by various methods differ considerably, complicating interpretation. Here, a previously identified plasma-based candidate secondary reference material (csRM) was modified into a serum-based two-leveled sRM. We validated its functionality to increase the equivalence between methods for international standardization. We applied technical procedures developed by the International Consortium for Harmonization of Clinical Laboratory Results. The sRM, consisting of lyophilized serum with cryolyoprotectant, appeared commutable among nine different measurement procedures using 16 native human serum samples in a first round robin (RR1). Harmonization potential of the sRM was simulated in RR1 and evaluated in practice in RR2 among 11 measurement procedures using three native human plasma samples. Comprehensive purity analysis of a candidate primary RM (cpRM) was performed by state-of-the-art procedures. The sRM was value assigned with an isotope dilution mass spectrometry-based candidate reference method calibrated using the certified pRM. The inter-assay CV without harmonization was 42.1% and 52.8% in RR1 and RR2, respectively. In RR1, simulation of harmonization with sRM resulted in an inter-assay CV of 11.0%, whereas in RR2 calibration with the material resulted in an inter-assay CV of 19.1%. Both the sRM and pRM passed international homogeneity criteria and showed long-term stability. We assigned values to the low (0.95 ± 0.11 nmol/L) and middle concentration (3.75 ± 0.17 nmol/L) calibrators of the sRM. Standardization of hepcidin is possible with our sRM, which value is assigned by a pRM. We propose the implementation of this material as an international calibrator for hepcidin-25. KW - Reference material KW - Peptide KW - Biomarker KW - Bioanalysis KW - Mass spectrometry KW - LC-MS/MS KW - Iron deficiency KW - MALDI-TOF MS KW - UHPLC-MS/MS KW - ELISA KW - Immunoassay PY - 2018 DO - https://doi.org/10.1515/cclm-2018-0783 SN - 1437-4331 SN - 1434-6621 VL - 57 IS - 6 SP - 864 EP - 872 PB - De Gruyter CY - Berlin AN - OPUS4-47153 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Abbas, Ioana M. A1 - Vranic, M. A1 - Hoffmann, Holger A1 - El-Khatib, Ahmed H. A1 - Montes-Bayón, M. A1 - Möller, H. M. A1 - Weller, Michael G. T1 - Investigations of the copper peptide hepcidin-25 by LC-MS/MS and NMR (+) JF - International Journal of Molecular Sciences N2 - Hepcidin-25 was identified as the main iron regulator in the human body, and it by binds to the sole iron-exporter ferroportin. Studies showed that the N-terminus of hepcidin is responsible for this interaction, the same N-terminus that encompasses a small copper(II)-binding site known as the ATCUN (amino-terminal Cu(II)- and Ni(II)-binding) motif. Interestingly, this copper-binding property is largely ignored in most papers dealing with hepcidin-25. In this context, detailed investigations of the complex formed between hepcidin-25 and copper could reveal insight into its biological role. The present work focuses on metal-bound hepcidin-25 that can be considered the biologically active form. The first part is devoted to the reversed-phase chromatographic separation of copper-bound and copper-free hepcidin-25 achieved by applying basic mobile phases containing 0.1% ammonia. Further, mass spectrometry (tandem mass spectrometry (MS/MS), high-resolution mass spectrometry HRMS)) and nuclear magnetic resonance (NMR) spectroscopy were employed to characterize the copper-peptide. Lastly, a three-dimensional (3D)model of hepcidin-25with bound copper(II) is presented. The identification of metal complexes and potential isoforms and isomers, from which the latter usually are left undetected by mass spectrometry, led to the conclusion that complementary analytical methods are needed to characterize a peptide calibrant or reference material comprehensively. Quantitative nuclear magnetic resonance (qNMR), inductively-coupled plasma mass spectrometry (ICP-MS), ion-mobility spectrometry (IMS) and chiral amino acid analysis (AAA) should be considered among others. KW - Metalloprotein KW - Peptide KW - Chromatography KW - High pH KW - Mobile phase KW - Metrology KW - Purity KW - Reference material KW - ATCUN KW - Copper KW - Nickel PY - 2018 UR - https://nbn-resolving.org/urn:nbn:de:kobv:b43-457796 UR - http://www.mdpi.com/1422-0067/19/8/2271 DO - https://doi.org/10.3390/ijms19082271 SN - 1422-0067 VL - 19 IS - 8 SP - 2271, 1 EP - 16 PB - MDPI CY - Basel AN - OPUS4-45779 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Abbas, Ioana M. A1 - Hoffmann, Holger A1 - Montes-Bayón, M. A1 - Weller, Michael G. T1 - Improved LC-MS/MS method for the quantification of hepcidin-25 in clinical samples JF - Analytical and Bioanalytical Chemistry N2 - Mass spectrometry-based methods play a crucial role in the quantification of the main iron metabolism regulator hepcidin by singling out the bioactive 25-residue peptide from the other naturally occurring N-truncated isoforms (hepcidin-20, -22, -24), which seem to be inactive in iron homeostasis. However, several difficulties arise in the MS analysis of hepcidin due to the sticky character of the peptide and the lack of suitable standards. Here, we propose the use of amino- and fluoro-silanized autosampler vials to reduce hepcidin interaction to laboratory glassware surfaces after testing several types of vials for the preparation of stock solutions and serum samples for isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS). Furthermore, we have investigated two sample preparation strategies and two chromatographic separation conditions with the aim of developing an LC-MS/MS method for the sensitive and reliable quantification of hepcidin-25 in serum samples. A chromatographic separation based on usual acidic mobile phases was compared with a novel approach involving the separation of hepcidin-25 with solvents at high pH containing 0.1% of ammonia. Both methods were applied to clinical samples in an intra-laboratory comparison of two LC-MS/MS methods using the same hepcidin-25 calibrators with good correlation of the results. Finally, we recommend an LC-MS/MS-based quantification method with a dynamic range of 0.5–40 μg/L for the assessment of hepcidin-25 in human serum that uses TFA-based mobile phases and silanized glass vials. KW - HPLC KW - Liquid chromatography KW - Mass spectrometry KW - Silanization KW - Mobile phase KW - Adsorption KW - Peptide losses KW - Recovery KW - Validation KW - Quality control KW - QC KW - Iron disorders KW - Chronic kidney disease KW - Metrology KW - Round robin exercise KW - Basic solvent KW - Peptide analysis PY - 2018 DO - https://doi.org/10.1007/s00216-018-1056-0 SN - 1618-2642 SN - 1618-2650 VL - 410 IS - 16 SP - 3835 EP - 3846 PB - Springer Nature CY - Heidelberg AN - OPUS4-45053 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Abbas, Ioana M. A1 - Hoffmann, Holger A1 - Weller, Michael G. T1 - Troubleshooting for the clinical measurement of iron biomarkers using LC-MS/MS: Suppression of sample losses in autosampler vials N2 - We developed a rapid and robust HPLC-MS/MS (QqQ) method for the quantification of hepcidin-25, a promising new biomarker in iron metabolism, in human samples. The novelty of the method is the use of special HPLC vials to avoid adsorptive losses due to the basic character of the peptide that causes interaction with the silanol groups of the vial’s glass surface. Up to 90% decrease in the MS/MS signal was observed, when commercial HPLC vials were used, while vials treated with 3-(2-aminoethylamino)propylmethyldimethoxysilane or 1H,1H,2H,2H-perfluorooctyltriethoxysilane, leading to no losses in the range of physiological hepcidin-25 mean serum levels (10-20 µg/L). T2 - MSACL 2017 EU CY - Salzburg, Austria DA - 10.09.2017 KW - Peptide losses KW - Adsorption KW - Silanization PY - 2017 AN - OPUS4-44613 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Abbas, Ioana M. A1 - Hoffmann, Holger A1 - Weller, Michael G. A1 - Montes-Bayon, M. T1 - Analytical strategies for the clinical assessment of the peptide hepcidin-25, a potential diagnostic tool in iron related disorders N2 - Hepcidin-25 has attracted much attention ever since its discovery in 2001. It is widely recognized that this liver produced peptide hormone plays a major role in the regulation of iron levels in mammals and can reveal important clinical information about several pathological states in patients suffering from iron-related disorders. With the aim to tackle the current difficulties in hepcidin quantification and improve the status of this promising biomarker in the clinical field, we developed a rapid and robust analytical strategy for the quantification of hepcidin-25 in human samples based on HPLC-MS/MS (QqQ) to be implemented in routine laboratories. The novelty of the method is the use of special HPLC vials to avoid adsorptive losses due to the basic character of the peptide that causes interaction with the silanol groups of the vial’s glass surface. Up to 90% decrease in the MS/MS signal was observed, when commercial HPLC vials were used, while vials treated with 3-(2-aminoethylamino)propylmethyl-dimethoxysilane or 1H,1H,2H,2H-perfluorooctyltriethoxysilane, leading to no significant losses in the dynamic range of physiological hepcidin-25 mean serum levels (10-20 µg/L). Careful analytical validation was performed for determining the reproducibility, repeatability, limit of quantification (0.5 µg/L) and linearity (0.5-40 µg/L) of the method. Serum samples from 9 healthy volunteers were analyzed with a median hepcidin-25 level of 3.3 µg/L, comparable to results reported in the literature. T2 - Australian Peptide Conference 2017 CY - Noosa Heads, Australia DA - 15.10.2017 KW - Validation KW - Hepcidin-25 KW - LC-MS/MS quantification PY - 2017 AN - OPUS4-44614 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Abbas, Ioana M. A1 - Hoffmann, Holger A1 - Weller, Michael G. T1 - An LC-MS/MS based reference method candidate for the clinical assessment of the promising iron biomarker hepcidin-25 in serum N2 - Hepcidin-25 has attracted much attention ever since its discovery in 2001. It is widely recognized that this peptide hormone plays a major role in the regulation of iron levels in mammals and can reveal important clinical information about several iron-related disorders. However, the development of a reliable assay to quantify hepcidin proved to be problematic and serum hepcidin-25 concentrations determined by various assays differ substantially. Challenges arise in the MS analysis of hepcidin due to the “sticky” character of the peptide and the lack of suitable standards. With the aim to tackle the current difficulties in hepcidin quantification and improve the status of this promising biomarker in the clinical field, we developed a rapid and robust analytical strategy for the quantification of hepcidin-25 in human samples based on HPLC-MS/MS (QqQ) as a reference method candidate to be implemented in routine laboratories. The novelty of the method is the use of amino- and fluoro-silanized autosampler vials to reduce hepcidin interaction to laboratory glassware surfaces. Furthermore, we have investigated two sample preparation strategies and two chromatographic separation conditions where the use of acidic mobile phases was compared with a novel approach involving solvents at high pH containing 0.1% of ammonia. Both methods were carefully validated and applied to clinical samples in an intra-laboratory comparison of two LC-MS/MS methods using the same hepcidin-25 calibrators with very good correlation of the results. T2 - European Mass Spectrometry Conference 2018 CY - Saarbrücken, Germany DA - 11.03.2018 KW - Validation KW - LC-MS/MS peptide quantification KW - Clinical samples PY - 2018 AN - OPUS4-44616 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Abbas, Ioana M. A1 - Schwaar, Timm A1 - Bienwald, Frank A1 - Weller, Michael G. T1 - Predictable Peptide Conjugation Ratios by Activation of Proteins with Succinimidyl Iodoacetate (SIA) JF - Methods and Protocols N2 - The small heterobifunctional linker succinimidyl iodoacetate (SIA) was examined for the preparation of peptide–protein bioconjugates with predicable conjugation ratios. For many conjugation protocols, the protein is either treated with a reductant to cleave disulfide bonds or is reacted with thiolation chemicals, such as Traut’s reagent. Both approaches are difficult to control, need individual optimization and often lead to unsatisfactory results. In another popular approach, a heterobifunctional linker with a N-hydroxysuccinimide (NHS) and a maleimide functionality is applied to the protein. After the activation of some lysine ε-amino groups with the NHS ester functionality, a cysteine-containing peptide is attached to the activated carrier protein via maleimide. Particularly, the maleimide reaction leads to some unwanted byproducts or even cleavage of the linker. Many protocols end up with conjugates with unpredictable and irreproducible conjugation ratios. In addition, the maleimide-thiol addition product should be assumed immunogenic in vivo. To avoid these and other disadvantages of the maleimide approach, we examined the known linker succinimidyl iodoacetate (SIA) in more detail and developed two protocols, which lead to peptide–protein conjugates with predefined average conjugation ratios. This holds potential to eliminate tedious and expensive optimization steps for the synthesis of a bioconjugate of optimal composition. KW - Bioconjugate KW - Carrier protein KW - Immunogen KW - Hapten KW - Linker KW - Antibody drug conjugate KW - ADC KW - Drug-to-antibody ratio KW - DAR KW - Conjugation ratio KW - Conjugation density KW - Carrier load KW - Click reaction KW - Click chemistry PY - 2017 UR - https://nbn-resolving.org/urn:nbn:de:kobv:b43-427188 UR - http://www.mdpi.com/2409-9279/1/1/2 DO - https://doi.org/10.3390/mps1010002 SN - 2409-9279 VL - 1 SP - 1 EP - 14 PB - MDPI CY - Basel, Schweiz AN - OPUS4-42718 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Abbas, Ioana M. A1 - Hoffmann, Holger A1 - Weller, Michael G. T1 - HPLC-MS/MS quantification of hepcidin-25, a new promising iron biomarker, in human serum samples N2 - Hepcidin-25 has attracted much attention ever since its discovery in 2001. It is widely recognized that this liver produced peptide hormone plays a major role in the regulation of iron levels in mammals. Hepcidin levels could reveal important clinical information about several pathological states in patients suffering from iron-related disorders such as chronic kidney disease (CKD) or hereditary haemochromatosis (HH). Despite significant efforts though, the development of a reliable assay to quantify hepcidin proved to be problematic for the last 15 years. With the aim to tackle the current difficulties in hepcidin quantification and improve the status of this promising biomarker in the clinical field, we developed a rapid and robust analytical strategy for the quantification of hepcidin-25 in human samples based on HPLC-MS/MS (QqQ) to be implemented in routine laboratories. The novelty of the method is the use of special HPLC vials to avoid adsorptive losses due to the basic character of the peptide that causes interaction with the silanol groups of the vial’s glass surface. Up to 90% decrease in the MS/MS signal was observed, when commercial HPLC vials were used, while vials treated with 3-(2-aminoethylamino)propylmethyl-dimethoxysilane or 1H,1H,2H,2H-perfluorooctyltriethoxysilane, leading to no significant losses in the dynamic range of physiological hepcidin-25 mean serum levels (10-20 µg/L). Careful analytical validation was performed for determining the reproducibility, repeatability, limit of quantification (0.5 µg/L) and linearity (0.5-40 µg/L) of the method. Serum samples from 9 healthy volunteers were analyzed with a median hepcidin-25 level of 3.3 µg/L, comparable to results reported in the literature. T2 - Tag der Chemie 2017 CY - Berlin, Germany DA - 05.07.2017 KW - Hepcidin-25 KW - LC-MS/MS KW - Iron biomarker PY - 2017 AN - OPUS4-41193 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - THES A1 - Abbas, Ioana M. T1 - Development of LC-MS/MS methods for the quantitative determination of hepcidin-25, a key regulator of iron metabolism N2 - Isotope-dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) is emerging in the field of clinical chemistry and laboratory medicine as an alternative to immunoassays and is acknowledged as the MS “gold standard” for small biomolecule quantification. Hepcidin-25, a key iron-regulatory peptide hormone discovered in 2000, has revolutionized the understanding of iron disorders and its quantitative determination in biological samples should advance the management of iron-related pathology (diagnosis, prognosis and treatment). This study applied LC-MS/MS, using the triple quadrupole (QqQ) mass spectrometer, in a rapid and robust analytical strategy for the quantification of hepcidin-25 in human serum, to be implemented in routine laboratories. For this purpose, two sample preparation strategies and two complementary chromatographic separation conditions were investigated, where the use of acidic mobile phases (0.1% trifluoroacetic acid) was compared with a novel approach involving solvents at high pH (containing 0.1% ammonia). The application of these LC-MS/MS methods to human samples in an intra-laboratory comparison, using the same hepcidin-25 calibrators, yielded a very good correlation of the results. The LC-MS/MS employing trifluoroacetic acid-based mobile phases was selected as a highly sensitive (limit of quantification LOQ of 0.5 μg/L) and precise (coefficient of variation CV<15%) method and was recommended as a reference method candidate for hepcidin-25 quantification in real samples (in the dynamic range of 0.5-40 μg/L). One of the novel aspects of the methodology was the use of amino- and fluoro-silanized autosampler vials to reduce the interaction of the 25-residue peptide to laboratory glassware surfaces. Moreover, this LC-MS/MS method was used for an international round robin study, applying a secondary reference material as a calibrator. By determining the degree of equivalence between the results of the ten participating methodologies, the performance of the method developed in this study was found to be in the optimal range as defined by the International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR). In this work, the formation of hepcidin-25 complexes with copper(II) was investigated. The first reversed-phase chromatographic separation of hepcidin-25/Cu2+ and hepcidin-25 (copper “free”) was achieved by applying mobile phases containing 0.1% of ammonia (pH 11). LC-MS/MS and high-resolution mass spectrometry (Fourier-transform ion cyclotron resonance (FTICR) MS) were applied for the mass spectrometric characterization of the formed hepcidin-25-Cu(II) species at pH values of 11 and 7.4 respectively. A new species corresponding to hepcidin-25 complexed with two copper ions was identified at high pH. KW - Copper KW - LC-MS/MS KW - Chromatography KW - Mass spectrometry KW - Metal complex KW - Metalloprotein KW - Peptide KW - Metrology KW - Reference material PY - 2018 UR - https://nbn-resolving.org/urn:nbn:de:kobv:11-110-18452/20119-6 UR - https://edoc.hu-berlin.de/handle/18452/20119?show=full DO - https://doi.org/10.18452/19358 SP - 1 EP - 156 CY - Berlin AN - OPUS4-45780 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -